(CRBN) Corbion - Ratings and Ratios
Exchange: AS • Country: Netherlands • Currency: EUR • Type: Common Stock • ISIN: NL0010583399
CRBN: Lactic Acid, Derivatives, Enzymes, Minerals, Vitamins, Algae Ingredients
Corbion NV, a company with a rich history dating back to 1919, has established itself as a leading global supplier of innovative ingredient solutions. Its product portfolio includes a wide range of lactic acid and lactic acid derivatives, as well as other fermentation-based products, functional enzyme blends, minerals, vitamins, and algae ingredients. These ingredients cater to various industries, including food, home and personal care, animal nutrition, supplements, pharmaceuticals, medical devices, and bioplastics, providing customers with tailored solutions to meet their specific needs.
The company's extensive network of sales offices and distributors enables it to effectively market its products worldwide, ensuring a strong presence in key markets. This strategic approach allows Corbion NV to stay close to its customers, understand their requirements, and provide them with high-quality products and services. With a strong focus on research and development, the company continuously works to expand its product offerings and improve existing ones, driving growth and innovation in the industries it serves.
Formerly known as CSM NV, the company underwent a significant transformation in 2013, adopting the name Corbion NV in October of that year. This rebranding reflected the company's evolving strategy and commitment to delivering sustainable and innovative solutions to its customers. Headquartered in Amsterdam, the Netherlands, Corbion NV is listed on the Euronext Amsterdam stock exchange under the ticker symbol CRBN, with its common stock traded under the ISIN code NL0010583399. As a specialty chemicals company, Corbion NV operates within the GICS Sub Industry of Specialty Chemicals, further underscoring its focus on developing and marketing high-performance ingredients for a wide range of applications.
Through its website, https://www.corbion.com, Corbion NV provides stakeholders with access to detailed information about its products, services, and sustainability initiatives. With a long history of delivering value to its customers and shareholders, the company remains committed to driving growth, innovation, and sustainability in the industries it serves, while maintaining its position as a leading player in the global specialty chemicals market.
Additional Sources for CRBN Stock
CRBN Stock Overview
Market Cap in USD | 1,292m |
Sector | Basic Materials |
Industry | Specialty Chemicals |
GiC Sub-Industry | Specialty Chemicals |
IPO / Inception |
CRBN Stock Ratings
Growth 5y | -17.1% |
Fundamental | 67.7% |
Dividend | 49.2% |
Rel. Strength Industry | 332 |
Analysts | - |
Fair Price Momentum | 23.32 EUR |
Fair Price DCF | 9.22 EUR |
CRBN Dividends
Dividend Yield 12m | 3.06% |
Yield on Cost 5y | 2.66% |
Annual Growth 5y | 4.86% |
Payout Consistency | 92.2% |
CRBN Growth Ratios
Growth Correlation 3m | -54.6% |
Growth Correlation 12m | 82.1% |
Growth Correlation 5y | -71.5% |
CAGR 5y | -2.73% |
CAGR/Mean DD 5y | -0.08 |
Sharpe Ratio 12m | 0.77 |
Alpha | 6.24 |
Beta | 0.66 |
Volatility | 31.72% |
Current Volume | 42.8k |
Average Volume 20d | 72.6k |
As of January 22, 2025, the stock is trading at EUR 23.22 with a total of 42,810 shares traded.
Over the past week, the price has changed by +4.41%, over one month by +8.10%, over three months by -6.67% and over the past year by +45.14%.
Yes, based on ValueRay Fundamental Analyses, Corbion (AS:CRBN) is currently (January 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 67.72 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CRBN as of January 2025 is 23.32. This means that CRBN is currently overvalued and has a potential downside of 0.43%.
Corbion has no consensus analysts rating.
According to ValueRays Forecast Model, CRBN Corbion will be worth about 25.3 in January 2026. The stock is currently trading at 23.22. This means that the stock has a potential upside of +8.87%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 26 | 12% |
Analysts Target Price | - | - |
ValueRay Target Price | 25.3 | 8.9% |